|Predicted||Bovine, Chicken, Mouse, Rat|
|Calculated MW||90 KDa|
|Other Names||Ribosomal protein S6 kinase alpha-2, S6K-alpha-2, 90 kDa ribosomal protein S6 kinase 2, p90-RSK 2, p90RSK2, MAP kinase-activated protein kinase 1c, MAPK-activated protein kinase 1c, MAPKAP kinase 1c, MAPKAPK-1c, Protein-tyrosine kinase Mpk-9, Ribosomal S6 kinase 3, RSK-3, pp90RSK3, Rps6ka2, Mapkapk1c, Rsk3|
|Target/Specificity||Synthetic peptide corresponding to amino acid residues from the C-terminal region conjugated to KLH.|
|Format||Prepared from rabbit serum by affinity purification via chromatography on an affinity column made with the C-terminal peptide used as antigen.|
|Antibody Specificity||Specific for ~90k RSK2 protein.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Ribosomal S6 Kinase 2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The p90 ribosomal S6 kinases (RSK)1–4 are downstream members of the extracellular signal-regulated kinase (ERK)/MAPK cascade . The loss of RSK2 activity in humans leads to Coffin–Lowry syndrome, which is characterized by mental retardation and growth deficits (Hanauer and Young, 2002). Recent work suggests that RSK2 exerts a tonic regulation on G-protein coupled signaling (Sheffler et al., 2006).
Hanauer A, Young ID (2002) Coffin-Lowry syndrome:
clinical and molecular features. J Med Genet
Sheffler DJ, Kroeze WK, Garcia BG, Deutch AY, Hu
feisen SJ, Leahy P, Bruning
JC, Roth BL (2006) p90
ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling. Proc Natl Acad Sci
If you have any additional inquiries please email technical services at email@example.com.